U.S. Sex Reassignment Hormone Therapy Market Size, Share & Trends Analysis Report By Gender Transition (Male-To-Female, Female-To-Male), By Type (Puberty Blockers, Estrogen), By Distribution Channel, And Segment Forecasts, 2023 - 2030

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation and Scope
                         1.1.1. Segment Definitions
                              1.1.1.1. Gender Transition Segment
                              1.1.1.2. Type Segment
                              1.1.1.3. Distribution Channel Segment
                    1.2. Regional Scope
                    1.3. Estimates and Forecast Timeline
                    1.4. Objectives
                         1.4.1. Objective - 1
                         1.4.2. Objective - 2
                         1.4.3. Objective - 3
                    1.5. Research Methodology
                    1.6. Information Procurement
                         1.6.1. Purchased Database
                         1.6.2. GVR’s Internal Database
                         1.6.3. Secondary Sources
                         1.6.4. Primary Research
                    1.7. Information or Data Analysis
                         1.7.1. Data Analysis Models
                    1.8. Market Formulation & Validation
                    1.9. Model Details
                         1.9.1. Commodity Flow Analysis
                    1.10. List of Secondary Sources
                    1.11. List of Abbreviations
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Gender Transition and Type Snapshot
                    2.3. Distribution Channel Snapshot
                    2.4. Competitive Insights
Chapter 3. U.S. Sex Reassignment Hormone Therapy Market Variables, Trends & Scope
                    3.1. Market Lineage Outlook
                         3.1.1. Parent market outlook
                         3.1.2. Related/ancillary market outlook
                    3.2. Penetration & Growth Prospect Mapping
                    3.3. Industry Value Chain Analysis
                         3.3.1. Reimbursement framework
                    3.4. Market Dynamics
                         3.4.1. Market driver analysis
                              3.4.1.1. Increasing Awareness About Sex Reassignment Treatments
                              3.4.1.2. Increasing Novel Hormonal Therapies with Better Efficacy
                         3.4.2. Market restraint analysis
                              3.4.2.1. Legal Challenges On Off-Label Use Of Sex Reassignment Drugs
                              3.4.2.2. Ambiguous Regulatory And Reimbursement Scenario For Sex Reassignment Drugs
                    3.5. U.S. Sex Reassignment Hormone Therapy Market Analysis Tools
                         3.5.1. Industry Analysis - Porter’s
                              3.5.1.1. Supplier power
                              3.5.1.2. Buyer power
                              3.5.1.3. Substitution threat
                              3.5.1.4. Threat of new entrant
                              3.5.1.5. Competitive rivalry
                         3.5.2. PESTEL Analysis
                              3.5.2.1. Political landscape
                              3.5.2.2. Technological landscape
                              3.5.2.3. Economic landscape
                         3.5.3. Major Deals & Strategic Alliances Analysis
                         3.5.4. Market Entry Strategies
Chapter 4. U.S. Sex Reassignment Hormone Therapy Market: Gender Transition Estimates & Trend Analysis
                    4.1. U.S. Sex Reassignment Hormone Therapy Market: Gender Transition Movement Analysis
                         4.1.1. Male-To-Female
                              4.1.1.1. Male-To-Female market estimates and forecast 2018 to 2030 (USD Million)
                         4.1.2. Female-To-Male
                              4.1.2.1. Female-To-Male market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. U.S. Sex Reassignment Hormone Therapy Market: Type Estimates & Trend Analysis
                    5.1. U.S. Sex Reassignment Hormone Therapy Market: Type Movement Analysis
                         5.1.1. Puberty Blockers
                              5.1.1.1. Puberty Blockers market estimates and forecast 2018 to 2030 (USD Million)
                         5.1.2. Estrogen
                              5.1.2.1. Estrogen market estimates and forecast 2018 to 2030 (USD Million)
                         5.1.3. Testosterone
                              5.1.3.1. Testosterone market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. U.S. Sex Reassignment Hormone Therapy Market: Distribution Channel Estimates & Trend Analysis
                    6.1. U.S. Sex Reassignment Hormone Therapy Market: Distribution Channel Movement Analysis
                         6.1.1. Hospital Pharmacies
                              6.1.1.1. Hospital Pharmacies market estimates and forecast 2018 to 2030 (USD Million)
                         6.1.2. Retail Pharmacies
                              6.1.2.1. Retail Pharmacies market estimates and forecast 2018 to 2030 (USD Million)
                         6.1.3. Others
                              6.1.3.1. Others market estimates and forecast 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
                    7.1. Recent Developments & Impact Analysis, By Key Market Participants
                    7.2. Company/Competition Categorization
                         7.2.1. Innovators
                    7.3. Vendor Landscape
                         7.3.1. List of key distributors and channel partners
                         7.3.2. Key customers
                         7.3.3. Key company market share analysis, 2022
                         7.3.4. Viatris Inc.
                              7.3.4.1. Company overview
                              7.3.4.2. Financial performance
                              7.3.4.3. Product benchmarking
                              7.3.4.4. Strategic initiatives
                         7.3.5. AbbVie Inc.
                              7.3.5.1. Company overview
                              7.3.5.2. Financial performance
                              7.3.5.3. Product benchmarking
                              7.3.5.4. Strategic initiatives
                         7.3.6. ASCEND Therapeutics US, LLC.
                              7.3.6.1. Company overview
                              7.3.6.2. Financial performance
                              7.3.6.3. Product benchmarking
                              7.3.6.4. Strategic initiatives
                         7.3.7. Pfizer Inc.
                              7.3.7.1. Company overview
                              7.3.7.2. Financial performance
                              7.3.7.3. Product benchmarking
                              7.3.7.4. Strategic initiatives
                         7.3.8. Lilly (Eli Lilly)
                              7.3.8.1. Company overview
                              7.3.8.2. Financial performance
                              7.3.8.3. Product benchmarking
                              7.3.8.4. Strategic initiatives
                         7.3.9. Novartis AG
                              7.3.9.1. Company overview
                              7.3.9.2. Financial performance
                              7.3.9.3. Product benchmarking
                              7.3.9.4. Strategic initiatives
                         7.3.10. Endo International plc
                              7.3.10.1. Company overview
                              7.3.10.2. Financial performance
                              7.3.10.3. Product benchmarking
                              7.3.10.4. Strategic initiatives

List of Tables

Table 1 List of abbreviations
Table 2 List of secondary sources
Table 3 U.S. sex reassignment hormone therapy market, by gender transition, 2018 - 2030 (USD Million)
Table 4 U.S. sex reassignment hormone therapy market, by therapy type, 2018 - 2030 (USD Million)
Table 5 U.S. sex reassignment hormone therapy market, by distribution channel, 2018 - 2030 (USD Million)

List of Figure

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. sex reassignment hormone therapy market: market outlook
Fig. 9 U.S. sex reassignment hormone therapy market competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 U.S. sex reassignment hormone therapy market driver impact
Fig. 15 U.S. sex reassignment hormone therapy market restraint impact
Fig. 16 U.S. sex reassignment hormone therapy market strategic initiatives analysis
Fig. 17 U.S. sex reassignment hormone therapy market: Gender transition movement analysis
Fig. 18 U.S. sex reassignment hormone therapy market: Gender transition outlook and key takeaways
Fig. 19 Male-To-Female market estimates and forecast, 2018 - 2030
Fig. 20 Female-To-Male market estimates and forecast, 2018 - 2030
Fig. 21 U.S. sex reassignment hormone therapy market: Type movement analysis
Fig. 22 U.S. sex reassignment hormone therapy market: Type outlook and key takeaways
Fig. 23 Puberty blockers market estimates and forecast, 2018 - 2030
Fig. 24 Estrogen market estimates and forecast, 2018 - 2030
Fig. 25 Testosterone market estimates and forecast, 2018 - 2030
Fig. 26 U.S. sex reassignment hormone therapy market: Distribution channel movement analysis
Fig. 27 U.S. sex reassignment hormone therapy market: Distribution channel outlook and key takeaways
Fig. 28 Hospital pharmacies market estimates and forecast, 2018 - 2030
Fig. 29 Retail pharmacies market estimates and forecast, 2018 - 2030
Fig. 30 Others market estimates and forecast, 2018 - 2030
Fig. 31 Participant categorization- U.S. sex reassignment hormone therapy market
Fig. 32 Market share of key market players- U.S. sex reassignment hormone therapy market